Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright restated their buy rating on shares of Kronos Bio (NASDAQ:KRON – Get Rating) in a research note issued to investors on Monday, Benzinga reports. The firm currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Kronos Bio’s Q1 2023 earnings at ($0.18) EPS, Q2 2023 earnings at […]
Kronos Bio (NASDAQ:KRON – Get Rating) and Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership. Institutional and Insider Ownership 63.4% of Kronos Bio shares […]
Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 -- Kronos Bio, Inc. , a company... | April 11, 2023
Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 -- Kronos Bio, Inc. , a company... | June 20, 2023
/PRNewswire/ -- The "Global SYK Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. This report...